If you have been reading about Maleimide chemistry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
=== Barley straw === Barley straw, in the United Kingdom, is placed in mesh bags and floated in fish ponds or water gardens to help reduce algal growth without harming pond plants and animals. Barley straw has not been approved by the United States Environmental Protection Agency (EPA) for use as a pesticide and its effectiveness as an algaecide in ponds has produced mixed results during university testing in the United States and the United Kingdom. It is unclear how straw actually works.
In Chinese, the most commonly used names are fěnsī (Chinese: 粉絲; lit. 'noodle thread') and fěntiáo or hóngshǔfěn (Chinese: 粉條 or Chinese: 紅薯粉; lit. 'noodle strip' or 'sweet potato noodles'). They are also marketed under the name saifun, the Cantonese pronunciation of the Mandarin xìfěn (Chinese: 細粉; lit. 'slender noodle', though the name fánsī (粉絲) is the term most often used in Cantonese. In China, glass noodles are a popular ingredient used in stir-fries, soups, and particularly hot pots. They can also be used as an ingredient in fillings for a variety of Chinese jiaozi (dumplings) and bing (flatbreads), especially in vegetarian versions of these dishes. Thicker glass noodles are also commonly used to imitate the appearance and texture of shark's fin in vegetarian soups. Thicker varieties, most popular in China's northeast, are used in stir-fries as well as cold salad-like dishes. A popular Shanghai cuisine using the ingredient is fried tofu with thin noodles (Chinese: 油豆腐線粉湯; pinyin: yóu dòu fu-xiàn fěn tāng). A popular Sichuan dish called "ants climbing a tree" consists of stewed glass noodles with a spicy ground pork meat sauce. In Tibetan cuisine, glass noodles are called phing or fing and are used in soup, in pork curry, or with mushrooms.
== Prognosis == Kwashiorkor is associated with a high risk of mortality and long-term complications. Treatment under the guidelines of the World Health Organization has proven to reduce this mortality risk and affected children tend to recover faster than children with other severe malnutrition diseases. However, physical and intellectual capabilities are not fully restored. Growth stunting and chronic disruption of microbiota are commonly observed after recovery. A high risk of death is identified by a brachial perimeter < 11 cm or by a weight-for-age threshold < −3 z-scores below the median of the WHO child growth standards. In practice, malnourished children with edema are suffering from potentially life-threatening severe malnutrition.
Keratolytic () therapy is a type of medical treatment to remove warts, calluses and other lesions in which the epidermis produces excess skin. In this therapy, acidic topical medicines, such as Whitfield's ointment or Jessner's solution, are applied to the lesion in order to thin the skin on and around it. This therapy causes the outer layer of the skin to loosen and shed. Keratolytics can also be used to soften keratin, a major component of the skin. This serves to improve the skin's moisture binding capacity, which is beneficial in the treatment of dry skin. Such agents (keratolytics) include alkalis (by swelling and hydrolysis of skin), salicylic acid, urea, lactic acid, allantoin, glycolic acid, and trichloroacetic acid. While cytostatic agents such as zinc pyrithione are first line, keratolytics (salicylic acid and sulfur) can also be used in the treatment of dandruff and seborrheic dermatitis. Sulfur and salicylic acid can also be used to effectively treat acne and cradle cap in some patients. Resorcinol is another keratolytic that is usually combined with sulfur. Urea acts as a keratolytic due to its hygroscopic property.
Sources: en.wikipedia.org
==== Cross-linking ==== Corneal collagen cross-linking is a developing treatment that aims to strengthen the cornea, however, according to a 2015 Cochrane review, there is insufficient evidence to determine if it is useful in keratoconus. In 2016, however, the FDA approved cross-linking surgery as a treatment for keratoconus and recommended that a registry system should be set-up to evaluate the long-term treatment effect. The Save Sight Keratoconus Registry is an international database of keratoconus patients that is tracking outcomes of cross-linking in patients with keratoconus.
===== MeSH D08.811.399.325 – cis-trans-isomerases (EC 5.2) ===== MeSH D08.811.399.325.500 – peptidylprolyl isomerase MeSH D08.811.399.325.500.400 – immunophilins MeSH D08.811.399.325.500.400.300 – cyclophilins MeSH D08.811.399.325.500.400.300.500 – cyclophilin A MeSH D08.811.399.325.500.400.700 – tacrolimus binding proteins MeSH D08.811.399.325.500.400.700.500 – tacrolimus binding protein 1a
== Cap snatching and transcription in influenza == Cap snatching is best described in influenza viruses, especially influenza A. In Orthomyxoviridae, the viral family of influenza, the RdRp is divided into three subunits: PA, PB1 and PB2. PB1 first binds the 5' end of the viral RNA (vRNA), activating PB2 and causing the 3' end of the vRNA to form a double-stranded zone with the 5' end. The PB2 proceeds to bind cellular mRNA at the N7-methyl guanosine (m7G) capped 5' end. The PA subunit subsequently cleaves the sequence 10-13 nucleotides from the cap structure via endonuclease activity at the N terminus. The exact cleavage location is dependent both on the distance between the PB2 and the PA of the RdRp (around 50 angstroms or 10-13 nucleotides) and also the sequence of the mRNA. Then, the PB1 subunit, which contains the polymerase activity, initially adds on two new nucleotides. The cap snatched primer moves through the product exit tunnel in the PB1 domain to serve as the primer for transcription. The vRNA 3'-UCGUUUU nucleotides are not bound to the polymerase but rather are free for complementary binding with the capped RNA primer to confer stability. Transcription then begins with G or C residue on the 3' end of the capped primer. Finally, the PB1 subunit completes chain elongation in the canonical 5' to 3' direction, releasing the cap, but keeping the 5' end bound. The viral 3' poly-A tail is added at the end of transcription by polymerase stuttering from the steric hindrance of the vRNA loop.
Significant increases in central MP levels were also observed after just two weeks of supplementation. Furthermore, in patients who had an atypical MP distribution in the eye (i.e., they did not have a high concentration of pigment in the centre of the macula), when supplemented with a meso-zeaxanthin-dominant supplement for 8 weeks, the normal pigment profile was reinstated, whereas this was not the case when patients were supplemented with a formulation lacking meso-zeaxanthin. The main findings from the MOST trials in patients with AMD were published in 2013 and 2015. The series of publications from these trials concluded, "Augmentation of the MP optical density across its spatial profile and enhancements in contrast sensitivity were best achieved after supplementation with a formulation containing high doses of meso-zeaxanthin in combination with lutein and zeaxanthin". Also, the final publication from this work, published in 2015, concluded that, "The inclusion of meso-zeaxanthin in a supplement formulation seems to confer benefits in terms of MP augmentation and in terms of enhanced contrast sensitivity in subjects with early AMD.". In 2016 and 2017, the results of two small clinical trials were published. The first trial, the CREST (Central Retinal Enrichment Supplementation Trials) study involved 105 normal healthy volunteers who underwent a series of complex tests of vision and were supplemented over 12 months.
== Pharmacology == Thiazide and thiazide-like diuretics are among the most efficacious and used drugs for the treatment of hypertension, edema, and major cardiovascular outcomes. Despite more than six decades of clinical use, the mechanism of action by which these drugs cure hypertension after long-term use had remained mysterious. Recently, Garau Gianpiero and co-authors reported that the membrane enzyme NAPE-PLD is a renal and extrarenal target of hydrochlorothiazide, chlortalidone and indapamide, shedding light on their mechanism of action in the treatment of hypertension and cardiovascular diseases. As revealed by the crystal structures of NAPE-PLD in complex with hydrochlorothiazide and pyridoxal phosphate (PLP), thiazide molecules bind within the 9 Angostrom-wide internal channel of NAPE-PLD in a manner competitive with the cofactor PLP. In the presence of bile acids, the association of NAPE-PLD with membranes creates membrane pores as dynamic conductive pathways through which the charged PLP can diffuse through cell membranes and membranes of subcellular compartments (e.g., mitochondria and peroxisome). The fact that thiazide medications promote beneficial effects that involve directly a main protein of the endocannabinoid system, NAPE-PLD, reveals not only a novel target for cardiovascular disease, but a way to modulate efficaciously the endocannabinoid system in therapy. These results can be useful in the management of vascular risk factors,as well as associated leukoencephalopathy and demyelinating disease.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.